drugset
drugset / Trial / NCT04973111

A Study to Assess CT-868 and the Relationship Between Insulin Secretory Response and Ambient Blood Glucose

NCT04973111 ↗

Phase 1 Completed 32 enrolled Carmot Therapeutics, Inc.
RandomizedCrossoverQuadruple-blindTreatment

Summary

A Study to Assess the Effect of CT-868 and the Relationship Between Insulin Secretory Response and Ambient Blood Glucose in Obese Male Subjects and Subjects with T2DM.

Timeline

Start
2021-07-16
Primary completion
2022-04-22
Completion
2022-04-22

Drugs

EvaluationDrugModalityDoseRoute
Subject CT-868 Unknown — Subcutaneous

Indications

diabetes mellitus